On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia

This publication has 15 references indexed in Scilit:

• Methotrexate pharmacokinetics and prognosis in osteosarcoma.
  Journal of Clinical Oncology, 1994
• Evaluation of Serious Adverse Events in Patients Treated with Protocols Including Methotrexate Infusions
  Pediatric Hematology and Oncology, 1994
• Serum Methotrexate (MTX) Concentrations and Prognosis in Patients with Osteosarcoma of the Extremities Treated with a Multidrug Neoadjuvant Regimen
  Journal of Chemotherapy, 1993
• Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
  Journal of Clinical Oncology, 1991
• The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia
  British Journal of Cancer, 1991
• MTX clearance is more important for intermediate-risk ALL.
  Journal of Clinical Oncology, 1990
• Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children
  Cancer, 1987
• Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia
  New England Journal of Medicine, 1986
• METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIA
  The Lancet, 1984
• Recent advances in the management of acute lymphocytic leukemia
  European Paediatric Haematology and Oncology, 1984